Literature DB >> 1621194

Lower survival rate for patients with carcinoma of the stomach of Borrmann type IV after gastric resection.

Y Maehara1, S Moriguchi, H Orita, Y Kakeji, M Haraguchi, D Korenaga, K Sugimachi.   

Abstract

Between 1965 and 1985, 194 of 1,113 patients (17.4 percent) with advanced carcinoma of the stomach who underwent gastric resection had Borrmann type IV carcinoma of the stomach, a macroscopically evident and diffusely spreading tumor. These patients tended to be younger and female and to have larger tumors that involved the entire stomach, as compared with patients with other types of carcinomas. Tissues were commonly undifferentiated, serosal invasion was prominent with infiltrative growth and high rates of metastasis to the lymph nodes and peritoneal dissemination were evident. In most instances, the disease was advanced; therefore, total gastrectomy was performed upon 82.0 percent of the patients and a palliative resection was done in 64.4 percent. The survival rate was lower than for patients with carcinoma of the stomach of other types (p less than 0.01). A multivariate analysis indicated that curative resection is an independent favorable prognostic event, while other factors are dependent covariates. Early detection of this carcinoma is crucial to extend survival time of patients with Borrmann type IV carcinoma of the stomach. Aggressive postoperative chemotherapy should be considered when a noncurative resection is done.

Entities:  

Mesh:

Year:  1992        PMID: 1621194

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  15 in total

Review 1.  Preoperative staging of gastric cancer as precondition for multimodal treatment.

Authors:  A Sendler; H J Dittler; H Feussner; H Nekarda; E Bollschweiler; U Fink; H Helmberger; H Höfler; J R Siewert
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

2.  Clinicopathological analysis of Borrmann type IV gastric cancer.

Authors:  Jeong Hwan Yook; Sung Tae Oh; Byung Sik Kim
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

Review 3.  Staging gastrointestinal cancer as a precondition for multimodal treatment.

Authors:  J R Siewert; A Sendler; H J Dittler; U Fink; H Höfler
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.

Authors:  Rieko Nakamura; Yoshiro Saikawa; Norihito Wada; Masashi Yoshida; Tetsuro Kubota; Koichiro Kumai; Masaki Kitajima
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

5.  Limited significance of curative surgery in Borrmann type IV gastric cancer.

Authors:  Eun Young Kim; Han Mo Yoo; Kyo Young Song; Cho Hyun Park
Journal:  Med Oncol       Date:  2016-06-01       Impact factor: 3.064

6.  Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis.

Authors:  Yifan Luo; Peng Gao; Yongxi Song; Jingxu Sun; Xuanzhang Huang; Junhua Zhao; Bin Ma; Yuan Li; Zhenning Wang
Journal:  World J Surg Oncol       Date:  2016-02-24       Impact factor: 2.754

7.  Reorganized Collagen in the Tumor Microenvironment of Gastric Cancer and Its Association with Prognosis.

Authors:  Zhi-Hua Zhou; Cheng-Dong Ji; Hua-Liang Xiao; Hai-Bin Zhao; You-Hong Cui; Xiu-Wu Bian
Journal:  J Cancer       Date:  2017-06-01       Impact factor: 4.207

8.  Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer.

Authors:  Hongliang Zu; Feng Wang; Yan Ma; Yingwei Xue
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

9.  Proliferative activity as a prognostic factor in Borrmann type 4 gastric carcinoma.

Authors:  Y Kakeji; Y Maehara; Y Adachi; H Baba; M Mori; M Furusawa; K Sugimachi
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma.

Authors:  Y Kakeji; Y Maehara; M Morita; A Matsukuma; M Furusawa; I Takahashi; T Kusumoto; S Ohno; K Sugimachi
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.